Cardiopulmonary toxicity after liposomal amphotericin B infusion.
about
Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding studySafety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients.Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles.A persistent challenge: the diagnosis of respiratory disease in the non-AIDS immunocompromised hostSafety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.Pulmonary reactions during treatment with amphotericin B: review of published cases and guidelines for management.Immediate hypersensitivity reaction following liposomal amphotericin-B (AmBisome) infusionLiposome opsonization.Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.Acute amphotericin B overdose.Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.Aerosolized liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in mice.Amphotericin B toxicity reduced by administration in fat emulsion.Amphotericin B--not so terrible.Amphotericin B and its delivery by liposomal and lipid formulations.Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity.Amphotericin B overdose in pediatric patients with associated cardiac arrest.Chest and back pain associated with a six-hour infusion of liposomal daunorubicin.Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics.
P2860
Q28286998-C055162F-33DF-41FA-920E-CD4FF9E27560Q30452906-00020572-0D7C-4B18-9F97-AE67A0AFE69EQ33409652-D724C8F9-9AC4-4C9A-9F7F-65EB3BC9216AQ33697079-8F1CA6D3-0257-4BC8-8B31-EDE4EA5FD155Q33749073-CC2A5284-FD16-4661-ABA5-DA76239B9835Q33922242-4B043704-679D-4D2C-B0BB-7CC81E9D4EB6Q33983629-F735B99F-32A3-4AB6-A961-571DECAC7540Q34350416-587781A3-5E18-4824-AF21-2E0EC0C334B7Q34513340-47913A31-6F8F-4E37-95ED-783D725BBC22Q36272611-DF2FEA94-14E7-4CBE-92FF-2E1D8034EB76Q36551607-1673A2BB-BFA4-47DA-B0D3-AB65CE97A2DDQ36647598-2D252B7B-6D91-4F35-BC24-A7C371E68F7FQ37613070-EEF3A196-603C-43B5-9ED3-339F1D435D9AQ39879675-1D087C3F-394A-427E-8A81-C1E9486D57BFQ40471190-E987E0A9-A2BE-4155-B5FB-60EA3197CA1DQ40605942-ECA5FF9F-F3D7-4CF7-B4D0-1F44EBCAC170Q40831603-85D102DB-430E-4216-A0CC-439E9855AAF5Q41966523-21E7357C-7E55-405A-AFC5-51E32B935E89Q42287924-F4631A36-F22B-46F1-9043-F6132B664AA3Q43504201-195A69CC-749E-4A56-9127-6159A7F957AEQ44440957-B9918F48-2B3F-441A-A04F-68A9B881AD4B
P2860
Cardiopulmonary toxicity after liposomal amphotericin B infusion.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh
1991年學術文章
@zh-hant
name
Cardiopulmonary toxicity after liposomal amphotericin B infusion.
@en
Cardiopulmonary toxicity after liposomal amphotericin B infusion.
@nl
type
label
Cardiopulmonary toxicity after liposomal amphotericin B infusion.
@en
Cardiopulmonary toxicity after liposomal amphotericin B infusion.
@nl
prefLabel
Cardiopulmonary toxicity after liposomal amphotericin B infusion.
@en
Cardiopulmonary toxicity after liposomal amphotericin B infusion.
@nl
P2093
P1476
Cardiopulmonary toxicity after liposomal amphotericin B infusion.
@en
P2093
Eichacker PQ
Lopez-Berestein G
Martinez A
Natanson C
P304
P356
10.7326/0003-4819-114-8-664
P407
P577
1991-04-01T00:00:00Z